Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Innovative 68Ga-DOTATOC PET-CT for neuroendocrine tumors
2013-003927-12Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jan 2014
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium Ga 68-edotreotide in apudoma (NET), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Primary: Diagnostic performance of 68Ga-DOTATOC PET-CT. Started Jan 2014; status: active.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
apudoma (NET)
Beyond the preview
Go deeper on 2013-003927-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003927-12.